Inhibrx Biosciences

Focus: Inhibrx Biosciences is an oncology-focused biotech company specializing in antibodies and fusion proteins, headquartered in La Jolla, CA. The company is in early-to-mid clinical development with a pipeline concentrated on immuno-oncology and rare/specialty cancers.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Inhibrx Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Inhibrx Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

INBRX-101/rhAAT-Fc

Alpha-1 Antitrypsin Deficiency

Phase 1

Clinical Trials (1)

NCT03815396Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

Phase 1

Help build intelligence for Inhibrx Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading pipeline in next-gen immuno-oncology with 7 active programs across Phase 1-3, including INBRX-106 (hexavalent OX40 agonist) in Phase 2/3 for HNSCC.
Specialized technical focus on antibody engineering and fusion protein platforms offers deep scientific expertise opportunity in high-value modalities.
La Jolla biotech hub location provides access to top talent pool and venture ecosystem for career mobility.

Watch Out For

Zero active job openings currently listed suggests potential hiring freeze or minimal near-term expansion.
Pre-revenue status with no disclosed funding or cash position creates significant financial uncertainty and restructuring risk.
Early pipeline stage (3 Phase 1, 2 Phase 2, 1 Phase 3) means 5+ years minimum to potential approval and revenue generation.

Generated by Claude from Inhibrx Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

INBRX-109

Ewing Sarcoma

Phase 1

Clinical Trials (1)

NCT03715933Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Phase 1

INBRX-105 - PDL1x41BB antibody

Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT03809624Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Phase 1